The Mevalonate Pathway and Renal Diseases: Experimental and Clinical Implications

Abstract

Get full access to this article

View all access options for this article.

References

Goldstein

J.L.

, Brown

M.S.

. Regulating of mevalonate pathway. Nature 1990; 343: 425–30.

O'Donnel

M.P.

, Kasiske

B.L.

, Kim

, Atluru

, Keane

W.F.

. The mevalonate pathway: importance in mesangial cell biology and glomerular disease. Miner Electrolyte Metab 1993; 19: 173–9.

L.L.

, Davies

J.E.

. Lipids and cellular Na⁺/H⁺ antiport activity in diabetic nephropathy. Kidney Int 1992; 42: 872–6.

Roullet

J.B.

, Xue

, Pappu

A.S.

, Roullet

, Holcomb

, McCarron

D.A.

. Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci USA 1993; 90: 11728–32.

Roullet

J.B.

, Xue

, Pappu

A.S.

Mevalonate availability affects human and rat resistance vessel function. J Clin Invest 1995; 96: 239–44.

Golper

T.A.

, Swartz

. Impaired renal mevalonate metabolism in nephrotic syndrome a stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemia Metabolism 1981; 31: 471–6.

Parker

T.S.

, McManara

D.J.

, Brown

C.D.

Plasma mevalonate as measure of cholesterol synthesis in man. J Clin Invest 1984; 74: 795–804.

Parker

T.S.

, McManara

D.J.

, Brown

C.D.

Mevalonic acid in human plasma: relationship of concentration and circadian rhyrhm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 1982; 79: 3037–41.

Jones

P.J.H.

, Pappu

A.S.

, Illingworth

D.R.

, Leitch

C.A.

. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur J Clin Invest 1992; 22: 609–13.

10.

Yoshida

, Honda

, Tanaka

, Matsuzaki

, He

, Osuga

. Simultaneous determination of mevalonate and 7-alphydroxy-cholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid bio-synthesis. J Cromatogr 1993; 613: 185–93.

11.

Scoppola

, Maher

V.M.G.

, Thompson

G.R.

, Rendell

N.B.

, Taylor

G.W.

. Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry. J Lipid Res 1991; 32: 1057–60.

12.

Brown

M.S.

, Goldstein

J.L.

. Multivalent feed-back regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21: 505–17.

13.

Carleberg

, Hjertman

, Wejde

, Larsson

. Mevalonate is essential for growth activation of human fibroblasts: evidence of a critical role of protein glycosylation in the prereplicative period. Experimental Cell Res 1994; 212: 359–66.

14.

Soma

, Baetta

, De Renzis

M.R.

In vivo enhanced antitumor activity of carmustine (N,N'-bis(2-chloroethyl)-N-nitrosourea) by simvastatin. Cancer Res 1995; 55: 597–602.

15.

Mallat

, Preaux

A.M.

, Blazejewski

, Dhumeaus

, Rosenbaum

, Mavier

. Effect of simvastatin, and inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology 1994; 20: 1589–94.

16.

Quesney-Huneeus

, Wiley

M.H.

, Siperstein

M.D.

. Essential role for mevalorate synthesis in DNA replication. Proc Natl Acad Sci USA 1979; 76: 5056–60.

17.

O'Donnel

M.P.

, Kasiske

B.L.

, Kim

, Atluru

, Keane

W.F.

. Lovastatin inhibit proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83–7.

18.

Jakobisiak

, Bruno

, Skiersky

J.S.

, Darzynkiewicz

. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 1991; 88: 3628–32.

19.

Quesney-Huneeus

, Galick

H.A.

, Siperstein

M.D.

, Erickson

S.K.

, Spencer

T.A.

, Nelson

J.A.

. The dual role of mevalonate in the cell cycle. J Biol Chem 1983; 258: 378–85.

20.

Fairbanks

K.P.

, Witte

L.D.

, Goodman

D.S.

. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem 1984; 259: 1546–51.

21.

Vigano

, Hernandez

, Corsini

. Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation. Eur J Pharmacol 1995; 291: 201–3.

22.

Corsini

, Mazzotti

, Raiteri

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG CoA reductase. Athero-sclerosis 1993; 101: 117–25.

23.

Corsini

, Bernini

, Quarato

Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996; 87: 458–68.

24.

Corsini

, Pazzucconi

, Pfister

, Paoletti

, Sirtori

C.R.

. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin (letter). Lancet 1996; 348: 1584.

25.

Motomura

, Saito

, Foegh

M.L.

. HMG CoA reductase inhibitors in organ transplantation. J Nephrol 1997; 10: 68–76.

26.

McPherson

, Tsoukas

, Baines

M.G.

. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439–44.

27.

Kobashigawa

J.A.

, Katznelson

, Laks

Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7.

28.

Totterman

T.H.

, Hanas

, Bergstrom

, Larsson

, Tufverson

. Immunologic diagnosis of kidney rejection using FACS analysis of graft-infiltrating functional and activated T and NK cell subjects. Transplantation 1989; 47: 817–23.

29.

Kirby

J.A.

, Givan

A.L.

, Shenton

B.K.

. Renal allograft rejection: possible involvement of antibody-dependent cell-mediated cytotoxicity. Transplantation 1990; 50: 225–9.

30.

Cutts

J.L.

, Scallen

T.J.

, Watson

, Bankhurst

A.D.

. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550–7.

31.

Cutts

J.L.

, Bankhurst

A.D.

. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990, 145: 244–52.

32.

Scoppola

, Lala

, Menzinger

. Effects of different hormones on mevalonic acid and circadian rhythm of cholesterol synthesis. Diabetes Nutrition Metabolism 1992; 5: 151–5.

33.

Scoppola

, Testa

, Frontoni

The effects of insulin on cholesterol synthesis in type II diabetes

Care 1995; 18: 1362–9.

34.

Naoumova

R.P.

, Marais

A.D.

, Mountney

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG CoA reductase inhibitors in familial hypercholesterolemia. Atheroscelrosis 1996; 119: 203–13.

35.

McNamara

D.J.

, Ahrens

E.H.

, Parker

T.S.

. Role of the kidneys in the metabolim of plasma mevalonate. J Clin Invest 1985; 76: 31–9.

36.

Kopito

R.K.

, Brunengrader

. (R)-mevalonate excretion in human and rat urines. Proc Natl Acad Sci USA 1980; 77: 5738–40.

37.

Scoppola

, De Paolis

, Menzinger

, Lala

, Di Giulio

. Plasma mevalonate concentrations in uremic patients. Kidney Int 1997; 5: 908–12.

38.

O'Donnel

M.P.

, Kasiske

B.L.

, Schmitz

P.G.

. Contrasting effects of lovastatin and enalapril on glomerular injury in Dahl salt-sensitive rats. Kidney Int 1990; 37: 391.

39.

Roullet

J.B.

, Xue

, Chapman

Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest 1996; 97: 2384–90.